Background. We evaluated if sleeve lobectomy had worse survival compared with pneumonectomy for nonsmall cell lung cancer (NSCLC) with N1 disease, which may be a risk factor for locoregional recurrence.
Background. We evaluated if sleeve lobectomy had worse survival compared with pneumonectomy for nonsmall cell lung cancer (NSCLC) with N1 disease, which may be a risk factor for locoregional recurrence.
Methods. Patients who underwent pneumonectomy or sleeve lobectomy without induction treatment for T2-3 N1 M0 NSCLC at a single institution from 1999 to 2011 were reviewed. Survival distribution was estimated with the Kaplan-Meier method, and multivariable Cox proportional hazards regression was used to evaluate the effect of resection extent on survival.
Results. Conclusions. Performing sleeve lobectomy instead of pneumonectomy for NSCLC with N1 nodal disease does not compromise long-term survival.
(Ann Thorac Surg 2014;97:230-5) Ó 2014 by The Society of Thoracic Surgeons L ung cancer is the leading cause of cancer death in the United States, where more than 220,000 new cases of lung cancer are diagnosed and more than 150,000 deaths occur each year [1] . Treatment of patients with non-small cell lung cancer (NSCLC) and tumor that involves the proximal bronchi can be challenging. One surgical option to ensure complete resection for these patients is pneumonectomy, which is associated with significant shortterm and long-term morbidity. In addition, patients with compromised lung function may not be able to tolerate such an extensive parenchymal resection.
A potential alternative for some patients with tumor located in central airways is sleeve lobectomy, where complete tumor resection is achieved by resection of the involved lobe along with a portion of central airway to achieve negative margins, with subsequent reconstruction of the airway to spare noninvolved lung parenchyma [2] . Sleeve lobectomy is considered oncologically equivalent to pneumonectomy when patients do not have nodal involvement of the lung cancer (N0 disease status) [3] [4] [5] [6] [7] [8] .
Not unexpectedly, the presence of nodal disease is associated with worse long-term survival for patients who undergo sleeve lobectomy than for patients without nodal disease [6, 7, 9, 10] . However, N1 disease involvement was identified as a significant risk factor for locoregional recurrence developing after sleeve lobectomy in a relatively small study in which N1 disease was present in only 18 of 49 patients who underwent sleeve lobectomy and in 11 of 49 patients who underwent pneumonectomy [3] . This finding has suggested that the presence of N1 lymph node involvement is a contraindication for sleeve lobectomy. The purpose of this study was to compare cancer recurrence and long-term survival between sleeve lobectomy and pneumonectomy in patients with NSCLC and N1 nodal involvement to evaluate oncologic efficacy. , only patients who had resection with  sleeve lobectomy or pneumonectomy of T2-3 N1 M0  (American Joint Committee on Cancer, Cancer Staging  Manual, 7 th edition) NSCLC, without induction chemotherapy or induction radiotherapy, were included for analysis. In general, sleeve lobectomy or pneumonectomy rather than standard lobectomy was only performed in a patient if his or her surgeon had determined that standard lobectomy could not achieve complete parenchymal resection.
From this cohort
The preoperative evaluation on whether a patient was considered an applicable candidate for the planned operation varied slightly amongst the surgeons during the study period, but generally was as follows: All patients underwent pulmonary function testing with diffusion measurements, which were then used to direct any subsequent workup. If the patient's pulmonary function tests were deemed adequate (forced expiratory volume in 1 second and diffusing capacity of the lung for carbon monoxide of at least 60% predicted), no subsequent evaluation was necessarily done.
When pulmonary function test results were considered potentially inadequate, patients underwent a quantitative differential ventilation-perfusion scan. The amount of perfusion to the planned area of resection and the pulmonary function test results were then used together to judge whether patients were adequate resection candidates. Exercise testing was used very selectively if patients were still felt to be borderline surgical candidates as determined by these test results.
The ability to tolerate potential pneumonectomy was assessed preoperatively for all patients in whom a sleeve resection was planned, and the decision on whether to perform pneumonectomy if a sleeve resection was not technically possible was made preoperatively. If a pneumonectomy was judged to be not appropriate for a patient, the operative plan was exploration only if sleeve resection could not be achieved. Exploration generally would begin with thoracoscopy in these patients, with thoracotomy performed if thoracoscopy showed that sleeve resection was potentially technically feasible. If sleeve resection was not performed after exploration by thoracoscopy or thoracotomy, the patients were closed and ultimately referred for evaluation of treatment with definitive chemotherapy and radiotherapy.
The staging workup for all patients with suspected or proven lung cancer generally included positron emission tomography, brain imaging, and cervical mediastinoscopy (at the same or a previous operative setting) to exclude metastatic disease. If patients had a mediastinoscopy that was negative for metastatic disease, additional mediastinal node sampling or dissection was not necessarily performed before resection at the time of the operation. Postoperative surveillance was surgeondependent but typically consisted of a computed tomography scan of the chest every 6 to 12 months for at least 5 years after resection.
Patterns of failure were assessed by means of follow-up imaging studies and information obtained from procedures such as computed tomography-guided transthoracic biopsies, bronchoscopy, and endobronchial ultrasound imaging. Locoregional recurrence was defined as recurrence of disease at the surgical resection margin or in lymph nodes in the ipsilateral hilum or in the mediastinum. All other sites of failure, including the supraclavicular fossa and contralateral hilum, were considered distant recurrences.
All operative and pathology reports were reviewed in detail to confirm stage and operative resection. Retrospective review was conducted of these patients' documented demographics, preoperative characteristics, and comorbidities, the histology and stage of disease, intraoperative details, and postoperative course. Because only patients who did not receive induction therapy were included, pathologic stage was listed in all patients.
Any postoperative event prolonging or otherwise altering the patient's postoperative course was recorded. Pneumonia was defined as a febrile illness with the presence of a new pulmonary infiltrate or positive sputum culture. Overall morbidity was defined as the occurrence of at least one postoperative event.
Also recorded were all operative deaths, which were defined as deaths that occurred within 30 days after the operation or that occurred later but during the same hospitalization. Deaths were captured by record review and through the Social Security Death Index Database.
Comparisons of patient characteristics among the two treatment groups were performed using the c 2 test for categoric variables (frequency and percentages) and the two-sample unpaired t test for continuous variables (mean and standard deviations). Overall survival included all deaths from any cause in the follow-up period, whereas patients alive were right-censored at the last available follow-up.
To compare survival between sleeve lobectomy and pneumonectomy, survival curves were initially constructed according to the Kaplan-Meier approach and compared using the log-rank test. Subsequently, a multivariable Cox proportional hazard model for survival was fitted. Adjustment in the multivariate analysis was performed for the covariates of resection extent (pneumonectomy vs sleeve lobectomy), age, tumor stage (stage III vs stage II), and tumor grade (poorly differentiated vs well or moderately differentiated). The number of covariates included in the Cox model was limited to these four due to the number of events observed in the cohort. The selected variables were chosen because they were felt to likely have the highest potential effect on survival of all the available variables. Results are presented as hazard ratios and 95% confidence intervals. All statistical analyses were performed using STATA/SE 11.2 (StataCorp LP, College Station, TX) and R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) software. The significance level a was set at 0.05, and two-sided p-values were calculated for all analyses.
Results
During the study period, 87 patients underwent surgical resection of T2-3 N1 M0 NSCLC, without induction chemotherapy or induction radiotherapy, by pneumonectomy (52 [60%]) or sleeve lobectomy (35 [40%]). Mediastinoscopy was performed before resection in 80 patients (92%). The pneumonectomies were right-sided in 19 (37%) and left-sided in 33 (63%). The sleeve lobectomies consisted of 20 (57%) right upper-lobe sleeve resections, 6 (17%) left upper-lobe sleeve resections, 6 (17%) left lowerlobe sleeve resections, 2 (6%) right lower-lobe sleeve resections, and 1 (3%) sleeve bilobectomy. During the same period, 148 patients underwent standard lobectomy or bilobectomy without induction chemotherapy or induction radiotherapy for T2-3 N1 M0 NSCLC.
Demographic, baseline characteristics, and comorbid conditions of the sleeve lobectomy and pneumonectomy patients are reported in Table 1 . Ages, sex distribution, and pulmonary function measurements were similar in pneumonectomy and sleeve lobectomy patients. Almost all of the patients in the two groups had a smoking history, although those in the pneumonectomy group had higher mean number of pack-years. Comorbidities were also similar between the two groups, with hypertension, coronary artery disease, and diabetes the most common concomitant medical problems. All patients underwent pulmonary function testing. Quantitative ventilationperfusion scans were used in 28 patients (32%), and exercise testing was used in 1 patient (1%).
Of the patients who underwent pneumonectomy, a sleeve resection was determined to be technically not possible in 24 (46%) before thoracotomy or thoracoscopy and that pneumonectomy would be necessary for complete resection. At the time of their operation, 28 pneumonectomy patients (54%) were felt to potentially be candidates for sleeve resection but were intraoperatively determined to require pneumonectomy. The reasons included tumor crossing the fissure to involve both the upper and lower lobes in 11 (39%), extent of bronchial involvement in 6 (21%), extent of pulmonary artery involvement in 6 (21%), extent of pulmonary vein involvement in 4 (14%), and an unknown reason in 1 (4%). Extent of nodal disease was not documented as precluding performance of sleeve resection in any patient.
Of the 35 patients who underwent sleeve resection, 34 (97%) required sleeve resection due to centrally located tumor at the bronchus. One patient (3%) who had a sleeve resection had a peripheral tumor, but had hilar nodal involvement, and sleeve resection was deemed necessary to avoid leaving residual disease. Table 2 summarizes pathologic and adjuvant treatment details. Mean tumor size was not significantly different between the two group nor was the distribution of stages or tumor differentiation. The use of adjuvant chemotherapy and radiotherapy was also not significantly different between the two groups. Overall, 85 of the 87 patients had R0 resections, defined as no residual gross or microscopic disease. Frozen section analysis of the bronchial margins was performed in 79 patients (91%). Frozen margins were negative in 76 of these patients and positive in 3. Microscopic disease was present in the final margins in 2 patients. One patient who underwent a sleeve right upper lobectomy had a positive bronchial margin and was treated with adjuvant concurrent chemoradiation (64 Gy targeted to the anastomosis, right hilum, and ipsilateral lower mediastinum, and four cycles of cisplatin/etoposide).
Another pneumonectomy patient had a positive microscopic vascular margin and was treated with adjuvant chemotherapy, but only tolerated one cycle of cisplatin/vinorelbine. Local recurrence did not develop, but metastatic disease did develop in the contralateral axilla 3 months after resection. More widespread metastatic disease developed subsequently, and the patient died 27 months after resection. Radiotherapy was used in 8 other patients postoperatively, who were felt by their treating clinicians to have high risk of local recurrence despite negative operative margins.
Postoperative events are listed in Overall morbidity was also not significantly different between the two groups. The most common events after pneumonectomy were atrial arrhythmias, need for transfusion, need for bronchoscopy, and the need for a nasoenteric or gastrostomy tube for nutrition. The most common events after sleeve lobectomy were atrial arrhythmias, need for bronchoscopy, and prolonged air leak.
The mean follow-up for the patients in the series was 38 AE 35 months, with a median follow-up of 27 months. Locoregional recurrences occurred in 9 patients (26%) who had a sleeve lobectomy and in 5 patients (10%) who had a pneumonectomy (p ¼ 0.07). The sites of local recurrences were the mediastinal lymph nodes in 9 patients (64%) overall (three mediastinal lymph node recurrences occurred after pneumonectomy and six occurred after sleeve resection), ipsilateral hilum after sleeve resection in 2 (14%), ipsilateral pleural space after pneumonectomy in 2 (14%), and distal mainstem bronchus after sleeve resection in 1 (7%). Distant recurrences occurred in 9 patients (26%) who had a sleeve lobectomy and in 13 (25%) who had a pneumonectomy (p ¼ 1). Of the 14 patients who had local recurrences, 7 also had distant recurrences: in 4 of these patients local and distant recurrences were found at the same time; 2 of these patients were initially found to have distant recurrences and later found to have local recurrences; and 1 patient was initially found to have a local recurrence, and then a distant recurrence was found 6 months later. Distant metastases also developed in 5 of the 9 patients with local recurrences after sleeve resection. The 4 who had local recurrences only were all treated with chemoradiation, and none required completion pneumonectomy. All 4 were alive at the time of their last follow-up.
The 3-year overall survival was 55.4% for all patients, and was 46.8% (95% confidence interval, 31.8% to 60.4%) after pneumonectomy and 65.2% (95% confidence interval, 45.5% to 79.3%) after sleeve lobectomy, which were not significantly different (p ¼ 0.23, Fig 1) . In multivariable survival analysis that included resection extent, age, stage, and grade, only increasing age predicted worse overall survival (Table 4) .
Comment
Sleeve lobectomy was initially developed as an alternative to pneumonectomy for patients with impaired cardiopulmonary reserve but has evolved to possibly be considered the standard of care for central or locally advanced NSCLC [2, [11] [12] [13] . Overall survival after sleeve lobectomy for patients with NSCLC ranges from 39% to 53% at 5 years and from 28% to 34% at 10 years [3, [5] [6] [7] [8] [9] [10] [11] [12] 14] . Although technically more challenging than pneumonectomy, sleeve lobectomy has been associated with superior 5-year survival rates, decreased operative mortality rates, and comparable locoregional recurrence and complication rates compared with pneumonectomy in several series [3, [11] [12] [13] [14] [15] . Sleeve lobectomy has also been shown to be more cost-effective and associated with higher quality of life than pneumonectomy [16, 17] . In the case of N0 disease, sleeve lobectomy is generally accepted as safe and associated with outcomes equal to or better than those obtained with pneumonectomy [3] [4] [5] [6] [7] [8] . The role of sleeve lobectomy in the setting of nodal disease has been considered controversial [2] . Not surprisingly, nodal disease has been seen to negatively affect survival after sleeve lobectomy [3] [4] [5] [6] [7] [8] [9] [10] 18] . In addition, another study showed that locoregional recurrences in patients with N1 disease were more common after sleeve lobectomy than after pneumonectomy [3] . In our study of 87 patients limited to T2-3 N1 M0 NSCLC treated with pneumonectomy or sleeve lobectomy, we did observe a trend toward higher locoregional recurrence after sleeve lobectomy, but overall survival after sleeve lobectomy and pneumonectomy was similar. These results suggest that performing a sleeve lobectomy rather than pneumonectomy for a central NSCLC with N1 disease does not compromise overall oncologic efficacy.
This study does have several limitations. Because all patients were from a single center, the results are not necessarily generalizable to other populations. The study is also retrospective and has a relatively small sample size. A higher local recurrence rate was observed after sleeve lobectomy, but the difference was not statistically significant.
Although our study may have been underpowered to show a significant difference, we did not see a similar trend for worse survival for sleeve lobectomy patients. In fact, better survival, despite the higher local recurrence rates, as well as less morbidity was seen after sleeve lobectomy. Some of these differences could be real, but the study may be underpowered to show differences between the sleeve lobectomy and pneumonectomy groups. In addition, the relatively small sample size particularly limits our ability to detect differences in more uncommon events such as perioperative mortality. A randomized controlled trial with a larger number of patients would be more ideal for testing our hypothesis; however, this relatively uncommon clinical scenario and the difficultly in conducting and enrolling patients in surgical trials makes it unlikely that an adequately powered randomized trial would ever be performed. Another limitation is that the survival analysis likely does not completely account for selection bias between the pneumonectomy patients and the sleeve lobectomy patients. Although tumor size and stage distribution were similar between the two groups, the fact that sleeve resection was not considered possible in the pneumonectomy patients does show that their extent of disease was at least somewhat more significant than that in the lobectomy patients. However, the analysis is not necessarily adjusted for this unmeasured potential confounder variable.
In conclusion, there was no statistically significant difference in survival between patients with T2-T3 N1 NSCLC who underwent pneumonectomy or sleeve lobectomy in this cohort. A higher rate of local recurrence was observed after sleeve lobectomy, but the result was not statistically significant. Although our study may have been underpowered to show a significant difference in local recurrence, a similar trend of worse survival for sleeve lobectomy patients was not seen. Our study suggests that sleeve lobectomy, if technically feasible, is an adequate oncologic resection of NSCLC when N1 disease is present.
